Issue · Healthcare

Healthcare (Substance Abuse)

Every healthcare bill, vote, and legislator stance in New Jersey, automatically classified by Maddy, our AI policy reader.

Total bills
4
2026-2027 Regular Session
Top supporter
-
no data yet
Top opponent
-
no data yet
Ranked legislators
0
0 support · 0 oppose
Showing 4 of 4 bills

All healthcare bills

in committee · New Jersey · Senate May 11, 2026

S 4123: Requires involuntary commitment of certain individuals who have been administered opioid antidotes.

This bill amends New Jersey law to automatically classify individuals who receive opioid overdose antidotes as 'dangerous to self,' thereby making them eligible for involuntary commitment to treatment. The change directly affects people treated for apparent opioid overdoses by linking emergency medical intervention to mental health commitment criteria. Under the new provisions, anyone administered an opioid antidote would be deemed unable to meet their own basic needs, which is one of the conditions required to force them into psychiatric care without their consent.
in committee · New Jersey · Senate May 4, 2026

S 4087: Requires DHS to establish system to ensure distribution of funds for certain support services for General Assistance beneficiaries ceases upon beneficiary's exit from support service.

This New Jersey bill requires the Department of Human Services to create a system that stops funding for substance use disorder treatment and housing once a General Assistance recipient leaves the service. The law authorizes officials to contact providers and beneficiaries to verify when services ended and to demand repayment from any provider who received funds for a client who is no longer receiving care. By mandating immediate cessation of payments upon discharge, the measure aims to prevent the state from paying for services that are no longer being delivered.
Sub-Topics Substance Abuse
in committee · New Jersey · Senate Mar 12, 2026

S 3904: Prohibits procurement of opioid antidotes from certain entities.

This bill prohibits New Jersey state agencies from purchasing opioid antidotes, such as naloxone, from pharmaceutical companies that have settled legal claims with the state over their role in the opioid epidemic. It requires that procurement requests for these medications be sent only to manufacturers and distributors that have not been part of such settlements, including their affiliates and subsidiaries. The law allows companies that agreed to supply antidotes as part of a settlement entered into before September 1, 2024, to continue providing them until their existing obligations are met. State agencies must also use available federal funding to purchase these medications only from vendors that meet the settlement-free criteria.
in committee · New Jersey · Senate Jan 13, 2026

S 538: Enhances requirements for applicant seeking to locate substance use disorder treatment center within 500 feet of school.

S 538 requires applicants seeking to locate a substance use disorder treatment center within 500 feet of a school to notify local municipal and county planning officials before submitting their main license application. It mandates that applicants also request a resolution of local support from the municipal governing body and submit this resolution along with their license application. This bill directly affects treatment center applicants who wish to operate near schools, adding a community engagement step to the approval process. The requirement applies to new applications submitted after the bill's effective date, modifying existing licensing procedures under New Jersey law. The bill does not change the definition of treatment centers or apply to existing applications filed before enactment.
Sub-Topics Substance Abuse